Report cover image

China Biopsy Market, Volume, Size, Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Publisher Renub Research
Published Oct 01, 2022
Length 200 Pages
SKU # RNBR17480735

Description

China Biopsy Market, Volume, Size, Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

China Biopsy Market is expected to reach US$ 7.54 Billion by 2027. Since 2000, the number of cancer cases and deaths and the crude incidence and mortality of cancer have continuously climbed in China. Long-term trends in cancer burden and rates reflect patterns in cancer-risk behaviors and changes in medical practice, such as the adoption of cancer screening tests. Furthermore, China is attempting to address its fast-rising cancer burden. However, rising population aging and the cumulative impact of risk factor exposure mean that cancer prevention faces many new obstacles.

Trends in China Biopsy Industry Prevailing Currently:

China is transitioning to developed-country cancer profiles, including high breast cancer rates, prostate cancer, lung cancer, liver cancer, thyroid cancer, colon and rectum cancer, kidney cancer, leukemia cancer, pancreatic cancer, and bladder cancer. These developments fuel a push for mass cancer screening and early detection among the 45 to 74-year-old group. As a result, China Biopsy Market Size is expected to expand at a CAGR of 6.25% during 2021-2027.

Although imaging procedures such as X-rays and CT scans can help detect areas of concern, they cannot distinguish between malignant and noncancerous cells. Consequently, a biopsy is the only reliable approach to identifying most cancers for cancer diagnosis. To lower the cancer burden in China, biopsy screening technologies and procedures have been developed. However, the most viable option in the near future may be to provide coordinated screening for high-risk locations and opportunistic screening for non-high-risk areas.

Key Companies Insights:

Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc. are among the important players profiled in our report. These market players in China contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.

How COVID-19 Affected the China Biopsy Test Industry?

The Coronavirus outbreak hit hard for China's biopsy diagnostics centers, hospitals, supply chain, and clinical trials. In addition, cancer diagnoses were being delayed, as they had been shut since the commencement of the COVID-19 pandemic, as diagnosis services and screening programs were put on halt.

Besides, during the pandemic, cancer patients also faced numerous challenges, including increased susceptibility to severe infection and interruptions in treatment or regular medical care. According to our results, the China Biopsy Test Market was negatively impacted from the end of 2019 to the beginning of 2020. However, according to our estimates, China Biopsy Market reached US$ 5.24 Billion in 2021 post recovery from the pandemic scenario.

Renub Research latest report “China Biopsy Market, Forecast By Market, Volume (Biopsy) & Diagnosed (Breast Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Thyroid Cancer, Kidney Cancer, Leukaemia and Bladder), Application Insights (Market, Volume (Biopsy) and Diagnosed), Companies (Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc.)” provides a detailed analysis of China Biopsy Industry.

Application Analysis –the Market has been covered from 8 viewpoints:

1. Breast Cancer
2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Kidney Cancer
7. Leukaemia
8. Bladder

Furthermore, the above mentioned application analysis have been covered from 3 viewpoints:

1. Market
2. Volume (Biopsy)
3. Diagnosed

Company Insights:

• Overview
• Initiatives/Recent Developments
• Financial Insight

Companies Covered:

1. Becton, Dickinson and Company
2. Thermo Fisher Scientific Inc
3. Bio-Rad Laboratories
4. Exact Sciences (Genomic Health)
5. Biocept
6. Biocartis
7. Roche Diagnostics
8. Myriad Genetics Inc.
9. Qiagen
10. NeoGenomics Laboratories
11. Quest Diagnostics Inc.

Table of Contents

200 Pages
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Market & Volume Analysis – China Biopsy Test
5.1 Market
5.2 Volume
6. Market & Volume Share Analysis – China Biopsy Test
6.1 Market Share
6.2 Volume Share
7. Application Analysis - China Biopsy Test Market
7.1 Breast Cancer
7.1.1 Market
7.1.2 Volume (Biopsy)
7.1.3 Diagnosed
7.2 Prostate Cancer
7.2.1 Market
7.2.2 Volume (Biopsy)
7.2.3 Diagnosed
7.3 Lung Cancer
7.3.1 Market
7.3.2 Volume (Biopsy)
7.3.3 Diagnosed
7.4 Liver Cancer
7.4.1 Market
7.4.2 Volume (Biopsy)
7.4.3 Diagnosed
7.5 Thyroid Cancer
7.5.1 Market
7.5.2 Volume (Biopsy)
7.5.3 Diagnosed
7.6 Kidney Cancer
7.6.1 Market
7.6.2 Volume (Biopsy)
7.6.3 Diagnosed
7.7 Colon & Rectum Cancer
7.7.1 Market
7.7.2 Volume (Biopsy)
7.7.3 Diagnosed
7.8 Pancreas Cancer
7.8.1 Market
7.8.2 Volume (Biopsy)
7.8.3 Diagnosed
7.9 Leukaemia
7.9.1 Market
7.9.2 Volume (Biopsy)
7.9.3 Diagnosed
7.10 Bladder
7.10.1 Market
7.10.2 Volume (Biopsy)
7.10.3 Diagnosed
8. Merger & Acquisition
9. Company Analysis
9.1 Becton, Dickinson and Company
9.1.1 Overview
9.1.2 Recent Developments
9.1.3 Financial Insight
9.2 Thermo Fisher Scientific Inc
9.2.1 Overview
9.2.2 Recent Developments
9.2.3 Financial Insight
9.3 Bio-Rad Laboratories
9.3.1 Overview
9.3.2 Recent Developments
9.3.3 Financial Insight
9.4 Exact Sciences (Genomic Health)
9.4.1 Overview
9.4.2 Recent Developments
9.4.3 Financial Insight
9.5 Biocept
9.5.1 Overview
9.5.2 Recent Developments
9.5.3 Financial Insight
9.6 Biocartis
9.6.1 Overview
9.6.2 Recent Developments
9.6.3 Financial Insight
9.7 Roche Diagnostics
9.7.1 Overview
9.7.2 Recent Developments
9.7.3 Financial Insight
9.8 Myriad Genetics Inc.
9.8.1 Overview
9.8.2 Recent Developments
9.8.3 Financial Insight
9.9 Qiagen
9.9.1 Overview
9.9.2 Recent Developments
9.9.3 Financial Insight
9.10 NeoGenomics Laboratories
9.10.1 Overview
9.10.2 Recent Developments
9.10.3 Financial Insight
9.11 Quest Diagnostics Inc.
9.11.1 Overview
9.11.2 Recent Developments
9.11.3 Financial Insight
List of Figures:
Figure-01: China – Biopsy Market (Million US$), 2017 – 2022
Figure-02: China – Forecast for Biopsy Market (Million US$), 2023 – 2027
Figure-03: China – Biopsy Volume (Million), 2017 – 2022
Figure-04: China – Forecast for Biopsy Volume (Million), 2023 – 2027
Figure-05: Application – Breast Cancer Market (Million US$), 2017 – 2022
Figure-06: Application – Forecast for Breast Cancer Market (Million US$), 2023 – 2027
Figure-07: Application – Breast Cancer Volume (Thousand), 2017 – 2022
Figure-08: Application – Forecast for Breast Cancer Volume (Thousand), 2023 – 2027
Figure-09: Application – Breast Cancer Diagnosed Volume (Number), 2017 – 2022
Figure-10: Application – Forecast for Breast Cancer Diagnosed Volume (Number), 2023 – 2027
Figure-11: Application – Prostate Cancer Market (Million US$), 2017 – 2022
Figure-12: Application – Forecast for Prostate Cancer Market (Million US$), 2023 – 2027
Figure-13: Application – Prostate Cancer Volume (Thousand), 2017 – 2022
Figure-14: Application – Forecast for Prostate Cancer Volume (Thousand), 2023 – 2027
Figure-15: Application – Prostate Cancer Diagnosed Volume (Number), 2017 – 2022
Figure-16: Application – Forecast for Prostate Cancer Diagnosed Volume (Number), 2023 – 2027
Figure-17: Application – Lung Cancer Market (Million US$), 2017 – 2022
Figure-18: Application – Forecast for Lung Cancer Market (Million US$), 2023 – 2027
Figure-19: Application – Lung Cancer Volume (Thousand), 2017 – 2022
Figure-20: Application – Forecast for Lung Cancer Volume (Thousand), 2023 – 2027
Figure-21: Application – Lung Cancer Diagnosed Volume (Number), 2017 – 2022
Figure-22: Application – Forecast for Lung Cancer Diagnosed Volume (Number), 2023 – 2027
Figure-23: Application – Liver Cancer Market (Million US$), 2017 – 2022
Figure-24: Application – Forecast for Liver Cancer Market (Million US$), 2023 – 2027
Figure-25: Application – Liver Cancer Volume (Thousand), 2017 – 2022
Figure-26: Application – Forecast for Liver Cancer Volume (Thousand), 2023 – 2027
Figure-27: Application – Liver Cancer Diagnosed Volume (Number), 2017 – 2022
Figure-28: Application – Forecast for Liver Cancer Diagnosed Volume (Number), 2023 – 2027
Figure-29: Application – Thyroid Cancer Market (Million US$), 2017 – 2022
Figure-30: Application – Forecast for Thyroid Cancer Market (Million US$), 2023 – 2027
Figure-31: Application – Thyroid Cancer Volume (Thousand), 2017 – 2022
Figure-32: Application – Forecast for Thyroid Cancer Volume (Thousand), 2023 – 2027
Figure-33: Application – Thyroid Cancer Diagnosed Volume (Number), 2017 – 2022
Figure-34: Application – Forecast for Thyroid Cancer Diagnosed Volume (Number), 2023 – 2027
Figure-35: Application – Kidney Cancer Market (Million US$), 2017 – 2022
Figure-36: Application – Forecast for Kidney Cancer Market (Million US$), 2023 – 2027
Figure-37: Application – Kidney Cancer Volume (Thousand), 2017 – 2022
Figure-38: Application – Forecast for Kidney Cancer Volume (Thousand), 2023 – 2027
Figure-39: Application – Kidney Cancer Diagnosed Volume (Number), 2017 – 2022
Figure-40: Application – Forecast for Kidney Cancer Diagnosed Volume (Number), 2023 – 2027
Figure-41: Application – Colon & Rectum Cance Market (Million US$), 2017 – 2022
Figure-42: Application – Forecast for Colon & Rectum Cance Market (Million US$), 2023 – 2027
Figure-43: Application – Colon & Rectum Cance Volume (Thousand), 2017 – 2022
Figure-44: Application – Forecast for Colon & Rectum Cance Volume (Thousand), 2023 – 2027
Figure-45: Application – Colon & Rectum Cance Diagnosed Volume (Number), 2017 – 2022
Figure-46: Application – Forecast for Colon & Rectum Cance Diagnosed Volume (Number), 2023 – 2027
Figure-47: Application – Pancreas Cancer Market (Million US$), 2017 – 2022
Figure-48: Application – Forecast for Pancreas Cancer Market (Million US$), 2023 – 2027
Figure-49: Application – Pancreas Cancer Volume (Thousand), 2017 – 2022
Figure-50: Application – Forecast for Pancreas Cancer Volume (Thousand), 2023 – 2027
Figure-51: Application – Pancreas Cancer Diagnosed Volume (Number), 2017 – 2022
Figure-52: Application – Forecast for Pancreas Cancer Diagnosed Volume (Number), 2023 – 2027
Figure-53: Application – Leukaemia Market (Million US$), 2017 – 2022
Figure-54: Application – Forecast for Leukaemia Market (Million US$), 2023 – 2027
Figure-55: Application – Leukaemia Volume (Thousand), 2017 – 2022
Figure-56: Application – Forecast for Leukaemia Volume (Thousand), 2023 – 2027
Figure-57: Application – Leukaemia Diagnosed Volume (Number), 2017 – 2022
Figure-58: Application – Forecast for Leukaemia Diagnosed Volume (Number), 2023 – 2027
Figure-59: Application – Bladder Market (Million US$), 2017 – 2022
Figure-60: Application – Forecast for Bladder Market (Million US$), 2023 – 2027
Figure-61: Application – Bladder Volume (Thousand), 2017 – 2022
Figure-62: Application – Forecast for Bladder Volume (Thousand), 2023 – 2027
Figure-63: Application – Bladder Diagnosed Volume (Number), 2017 – 2022
Figure-64: Application – Forecast for Bladder Diagnosed Volume (Number), 2023 – 2027
Figure-65: Becton, Dickinson and Company – Global Revenue (Million US$), 2017 – 2022
Figure-66: Becton, Dickinson and Company – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-67: Thermo Fisher Scientific Inc – Global Revenue (Million US$), 2017 – 2022
Figure-68: Thermo Fisher Scientific Inc – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-69: Bio-Rad Laboratories – Global Revenue (Million US$), 2017 – 2022
Figure-70: Bio-Rad Laboratories – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-71: Exact Sciences (Genomic Health) – Global Revenue (Million US$), 2017 – 2022
Figure-72: Exact Sciences (Genomic Health) – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-73: Biocept – Global Revenue (Million US$), 2017 – 2022
Figure-74: Biocept – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-75: Biocartis – Global Revenue (Million US$), 2017 – 2022
Figure-76: Biocartis – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-77: Roche Diagnostics – Global Revenue (Million US$), 2017 – 2022
Figure-78: Roche Diagnostics – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-79: Myriad Genetics Inc. – Global Revenue (Million US$), 2017 – 2022
Figure-80: Myriad Genetics Inc. – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-81: Qiagen – Global Revenue (Million US$), 2017 – 2022
Figure-82: Qiagen – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-83: NeoGenomics Laboratories – Global Revenue (Million US$), 2017 – 2022
Figure-84: NeoGenomics Laboratories – Forecast for Global Revenue (Million US$), 2023 – 2027
Figure-85: Quest Diagnostics Inc. – Global Revenue (Million US$), 2017 – 2022
Figure-86: Quest Diagnostics Inc. – Forecast for Global Revenue (Million US$), 2023 – 2027
List of Tables:
Table-01: China – Biopsy Test Market Share by Cancer Type (Percent), 2017 – 2022
Table-02: China – Forecast for Biopsy Test Market Share by Cancer Type (Percent), 2023 – 2027
Table-03: China – Biopsy Test Volume Share by Cancer Type (Percent), 2017 – 2022
Table-04: China – Forecast for Biopsy Test Volume Share by Cancer Type (Percent), 2023 – 2027

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us